Exploring the "chemo" in chemoimmunotherapy for triple-negative breast cancer.

In this issue of Cancer Cell, Zhang et al. use single-cell RNA sequencing to compare immune cell dynamics in triple-negative breast cancers treated with the PD-L1 inhibitor atezolizumab plus paclitaxel or nab-paclitaxel. They identify distinct T cell activation patterns and highlight mast cells' role in immune activation exclusively in the nab-paclitaxel combination.